Table 2 Study indication and areas of disagreement in TTE interpretation between fellows and attendings
Reason for disagreement | Primary TTE Indication | |||
|---|---|---|---|---|
LV function | Pericardial Effusion | Other | Total | |
LV size, LV function, LV wall motion abnormalities | 56 (63.6%) | 7 (15.6%) | 6 (19.4%) | 69 (42.1%) |
Valve Pathology | 13 (14.8%) | 4 (8.9%) | 12 (38.7%) | 29 (17.7%) |
Pericardial effusion | 2 (2.3%) | 25 (55.6%) | 1 (3.2%) | 28 (17.1%) |
RV size and function | 16 (18.2%) | 8 (17.8%) | 10 (32.3%) | 34 (20.7%) |
Other (LV hypertrophy, pulmonary hypertension, LVOT gradient) | 1 (1.1%) | 1 (2.2%) | 2 (6.5%) | 4 (2.4%) |
Total | 88 (53.7%) | 45 (27.4%) | 31 (18.9%) | 164 (100.0%) |